ElsevierDrugInformation
Vilobelimab Solution for Injection
Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
VILOBELIMAB (vil oh bel i mab) treats severe COVID-19 in people who are hospitalized. It works by slowing down an overactive immune system, which prevents worsening symptoms. It is a monoclonal antibody. The FDA has allowed the emergency use of this medication.
This medication is infused into a vein. It is given by your care team in a hospital or clinic setting.
Talk to your care team about the use of this medication in children. Special care may be needed.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
Interactions have not been studied.
This does not apply.
Visit your care team for regular checks on your progress. Your condition will be monitored carefully while you are receiving this medication. Tell your care team if your symptoms do not start to get better or if they get worse.
This medication may increase your risk of getting an infection. Call your care team for advice if you get a fever, chills, sore throat, or other symptoms of a cold or flu. Do not treat yourself. Try to avoid being around people who are sick.
Cookies are used by this site. To decline or learn more, visit our cookie notice.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.